enlightenbio  Blog

Tempus and LabCorp Announce Collaboration to Accelerate Clinical Trial Patient Participation

CHICAGO & BURLINGTON, N.C.–(BUSINESS WIRE)–Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, and LabCorp (NYSE: LH), a leading global life sciences company, today announced a collaboration with LabCorp’s drug development business, Covance. LabCorp will participate in Tempus’s TIME Trial® Network and the companies will work together to accelerate patient enrollment for oncology clinical trials through an innovative, data-driven approach that aims to transform the clinical trial model and modernize how they are designed and executed.

As novel therapies become increasingly targeted, identifying and enrolling patient populations have become a significant challenge for investigators and sites. Tempus offers a solution with its TIME Trial Program, which uses real-time clinical and molecular data to screen and match patients to biomarker-targeted trials. Institutions participating in The TIME Trial Network are able to initiate their trial on behalf of patients in as few as 10 days.

“The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network,” said Kim Blackwell, Chief Medical Officer of Tempus. “We’re excited to collaborate with LabCorp’s drug development business, Covance, and leverage their network of oncology sites and community physicians across the U.S., as well as their successful track record in executing some of the country’s most cutting-edge oncology trials. This collaboration furthers our mission to increase trial participation and ultimately bring the right treatment to the right patients at the right time.”

“LabCorp’s drug development business has extensive experience in executing clinical trials and our leadership position in oncology, coupled with Tempus’ innovative clinical trial model, provides thousands of physicians and patients easier access to more therapeutics,” said Dr. Paul Kirchgraber, CEO, LabCorp’s drug development business, Covance. “With oncology patient enrollment rates being in the single digits, it’s imperative that we find comprehensive approaches to accelerate oncology clinical trials and bring new treatments to patients faster. The combination of our capabilities will increase the ability to identify patients with specific genetic markers and link them to trial sites, thus greatly expanding access to hard-to-find patient pools for faster enrollment of the right patients for precision medicine oncology clinical trials.”

To learn more about the TIME Trial Program, visit www.tempus.com/clinical-trial-matching.

Author / source: LabCorp / https://www.businesswire.com/news/home/20200916005474/en/Tempus-and-LabCorp-Announce-Collaboration-to-Accelerate-Clinical-Trial-Patient-Participation

Press Release

Follow Me

Most popular

%d bloggers like this: